20 results on '"Fuchs CS"'
Search Results
2. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
3. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
4. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
5. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
6. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.
7. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
8. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
9. Cohort study of fatty acid synthase expression and patient survival in colon cancer.
10. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
11. Activity of sunitinib in patients with advanced neuroendocrine tumors.
12. Prediagnostic plasma folate and the risk of death in patients with colorectal cancer.
13. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer.
14. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
15. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
16. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
17. Adjuvant and neoadjuvant approaches in gastric cancer.
18. Diagnosis in oncology. Sign of Leser-Trélat in newly diagnosed advanced gastric adenocarcinoma.
19. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
20. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.